PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
With non-clinical CRO revenue declining for four straight years, the domestic label-change approval for ALS drug Neuronata-R and the upcoming US FDA Type C meeting have become the key swing factors for the company's near-term recovery.
2025 consolidated revenue fell to KRW 20.16bn from KRW 28.76bn a year earlier, with an operating loss of KRW 21.2bn marking a fourth consecutive year of losses.
Neuronata-R received a label-change approval from Korea's MFDS in May 2026 reflecting Phase 3 data, and the company requested a Type C meeting with the US FDA in August 2026.
The Q2 2026 net loss attributable to owners narrowed to KRW 3.68bn, a clear improvement from KRW 10.0bn in Q4 2025.
The non-clinical CRO segment, historically the bulk of revenue, continues to see order declines, while cell-therapy production has been suspended since early 2025 amid facility relocation and approval procedures.
The debt ratio improved from 301.0% in 2023 to 103.7% in 2025, but operating cash flow has remained negative every year in the period.
CorestemChemon operates two segments: a biopharmaceutical division developing stem cell-based cell therapies, and a non-clinical contract research organization (CRO) segment inherited from Chemon, which was absorbed via merger in 2022.
Its flagship product is Neuronata-R, an ALS (Lou Gehrig's disease) treatment using autologous bone marrow-derived mesenchymal stem cells that received conditional approval in Korea in 2014.
However, the non-clinical CRO segment has historically accounted for the overwhelming majority of revenue, with past filings showing CRO contributing more than 95% of sales while cell therapy products including Neuronata-R made up only a single-digit share.
The non-clinical CRO business provides pre-clinical animal testing services covering toxicity, safety, and efficacy evaluation, mainly to domestic pharmaceutical clients.
Cell therapy production is being relocated from the former Yongin GMP facility to an Advanced Therapy Medicinal Products (ATMP) center in the Osong Bio Science Complex, and normal production and sales require completion of GMP certification at the Osong site.
The company is also reported to hold a pipeline of stem cell therapy candidates targeting Parkinson's disease, neuromyelitis optica (NMO), and idiopathic pulmonary fibrosis (IPF).
In Korea's non-clinical CRO market, CorestemChemon (via Chemon) competes with several other listed and unlisted CRO providers, and recent earnings seasons have shown diverging performance across peers. In the cell therapy business, the company competes within a broader landscape of global ALS treatment developers.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩5.5B | -₩6.8B | −123.6% |
| 2025Q3 | ₩3.6B | -₩7.5B | −208.0% |
| 2025Q4 | ₩4.9B | -₩3.1B | −62.4% |
| 2026Q1 | ₩4.3B | -₩6B | −137.7% |
| 2026Q2 | ₩5.4B | -₩4.3B | −79.3% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩46.3B | -₩6B | ₩1B | −13.0% | 2.4% | 89.6% |
| 2023 | ₩33.7B | -₩19.7B | -₩17.7B | −58.5% | −90.2% | 301.0% |
| 2024 | ₩28.8B | -₩22B | -₩26.3B | −76.6% | −54.0% | 141.7% |
| 2025 | ₩20.2B | -₩21.2B | -₩26.8B | −105.3% | −48.6% | 103.7% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual revenue declined for four consecutive years, from KRW 46.29bn in 2022 to KRW 33.66bn in 2023, KRW 28.76bn in 2024, and KRW 20.16bn in 2025.
Over the same period, the operating loss widened from KRW 6.01bn in 2022 to KRW 19.68bn in 2023 and KRW 22.02bn in 2024 before narrowing slightly to KRW 21.22bn in 2025, though the faster pace of revenue decline pushed the operating margin from -13.0% in 2022 to -105.3% in 2025.
Net income attributable to owners swung from a small profit of KRW 1.00bn in 2022 to losses of KRW 17.67bn in 2023, KRW 26.25bn in 2024, and KRW 26.83bn in 2025, marking three straight years of substantial losses.
On a quarterly basis, the net loss widened from KRW 7.86bn in Q2 2025 and KRW 7.18bn in Q3 2025 to KRW 10.01bn in Q4 2025, before narrowing to KRW 6.94bn in Q1 2026 and KRW 3.68bn in Q2 2026, a visibly improving trend.
Revenue also bottomed at KRW 3.60bn in Q3 2025 before recovering somewhat to KRW 4.95bn, KRW 4.35bn, and KRW 5.40bn over the following three quarters.
Operating cash flow deteriorated from -KRW 8.42bn in 2022 to -KRW 15.70bn in 2023 and -KRW 21.12bn in 2024, then improved somewhat to -KRW 13.87bn in 2025, though cash generation remains weak overall.
Total equity fell to KRW 19.60bn in 2023 before rising to KRW 48.59bn in 2024 and KRW 55.17bn in 2025, a pattern consistent with capital-raising activity offsetting accumulated losses.
Total liabilities were roughly flat, moving from KRW 58.99bn in 2023 to KRW 57.20bn in 2025, but the debt ratio dropped sharply from 301.0% to 103.7% over the same span as equity was rebuilt.
Korea's non-clinical CRO industry has faced declining order intake in recent years amid a global economic slowdown and reduced biotech investment domestically, and CorestemChemon's CRO service revenue is reported to have continued declining from around KRW 27.5bn in 2023.
Across the sector, earnings seasons have shown diverging outcomes depending on individual firms' ability to recover order backlogs, meaning the timing of any broader CRO market normalization would directly affect CorestemChemon's revenue trajectory.
In the cell therapy segment, ALS treatment is widely regarded as a rare-disease area with substantial unmet medical need globally, and Neuronata-R drew attention domestically as one of the world's first approved neurological stem cell therapies in 2014.
However, since the Phase 3 trial failed to meet its primary endpoint across the overall patient population and only showed efficacy improvements in the slow-progressing subgroup, the scope of the eventual approved indication and addressable market size may end up constrained.
Competition in global ALS drug development, including in the United States, continues, and CorestemChemon has been building a global foothold through a North Carolina presence and participation in an NSF-supported regenerative medicine initiative led by the Wake Forest Institute for Regenerative Medicine.
Some observers also note that Korea's advanced biopharmaceutical review framework has shown a trend toward more flexible regulatory treatment of cell and gene therapies, which could serve as a reference point for the approval environment facing similar rare-disease therapies going forward.
The company set a full-year revenue target of KRW 50bn at the start of 2025, but actual revenue came in at only KRW 20.16bn, falling well short of that goal. Two factors stand out for the outlook.
First is the normalization of domestic Neuronata-R production and sales: following the May 2026 label-change approval, an equivalency test between the former Yongin plant and the new Osong facility must be completed before sales can meaningfully resume, and the company has said it plans to manufacture at the Osong ATMP center once GMP certification is granted there.
Second is the US market roadmap: the company requested an FDA Type C meeting in August 2026 and expects the meeting to take place before the end of October 2026 if procedures proceed smoothly, covering nine agenda items including interpretation of Phase 3 results and future BLA strategy.
The company has stated that inquiries from foreign patients seeking treatment have increased since Phase 3 completion, suggesting some baseline demand exists ahead of any approval-driven ramp.
That said, the company conservatively disclosed in a securities registration statement that it could consider raising funds through a sale of the Osong ATMP center or the non-clinical CRO business if the CRO market fails to normalize as expected in 2026, though a company representative later said such a sale is not currently under consideration.
CorestemChemon has posted net losses for several consecutive years, placing it in a range where conventional earnings-based valuation metrics are difficult to apply.
Its price-to-book ratio has tended to trade at a premium to net asset value, which may partly reflect expectations tied to upcoming approval or licensing events. The company has not paid dividends in recent years, limiting its appeal from a yield perspective.
Looking at the multi-year earnings pattern, the company moved from a brief profit in 2022 to consecutive losses from 2023 through 2025, though the most recent quarters show a gradual narrowing of loss size.
Whether this directional improvement continues will likely depend on the timing of Neuronata-R production normalization and the pace of any CRO order recovery.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Neuronata-R obtained a domestic label-change approval in May 2026 reflecting Phase 3 data. The company then requested an FDA Type C meeting in August, expected to occur before the end of October 2026 if procedures go smoothly.
The domestic approval could serve as a reference point for the US entry strategy, potentially linking to the next stage of the global pipeline's development.
Net loss attributable to owners narrowed for two consecutive quarters, from KRW 10.01bn in Q4 2025 to KRW 6.94bn in Q1 2026 and KRW 3.68bn in Q2 2026. Revenue has also shown a modest recovery since bottoming in Q3 2025. If this trend continues, it could be interpreted as an early signal of operational improvement.
Total equity grew from KRW 19.60bn in 2023 to KRW 55.17bn in 2025, and the debt ratio fell sharply from 301.0% to 103.7% over the same period. Capital raises appear to have provided some financial buffer despite persistent operating losses.
Consolidated revenue fell by more than half, from KRW 46.29bn in 2022 to KRW 20.16bn in 2025. The non-clinical CRO segment, which accounts for the bulk of revenue, is reported to have seen continued declines in contract testing service revenue, and uncertainty over order recovery remains a drag on any earnings rebound.
Operating cash flow was negative every year from 2022 through 2025. Media reports have noted that liquidity concerns emerged even after external capital raises, as available cash was reportedly depleted quickly.
The full impairment of KRW 3.9bn in goodwill recognized at the time of the Chemon acquisition also points to a decline in the perceived earnings value of the CRO business.
Neuronata-R's Phase 3 trial failed to meet its primary endpoint in the overall patient population, with efficacy confirmed only in the slow-progressing subgroup. This could constrain the eventual approved indication and revenue potential.
In addition, actual resumption of production and sales requires both GMP certification at the Osong plant and completed equivalency testing between the Yongin and Osong facilities, leaving timing uncertainty.
The outcome of the FDA Type C meeting and the subsequent BLA filing strategy have not yet been finalized. The domestic approval was also granted for a limited patient subgroup, so expansion of the indication and decisions by overseas regulators remain areas of uncertainty.
With operating cash flow remaining negative every year, the company may need additional external financing. Given the history of large capital raises, the possibility of further equity dilution cannot be ruled out.
The non-clinical CRO segment, which accounts for the bulk of revenue, has been significantly affected by the market downturn, and the company itself has noted it could consider divesting business units if the CRO market fails to normalize in 2026.
Given the small revenue contribution from the cell therapy business, the extent of any CRO market recovery has an outsized impact on overall results.
Check whether the FDA Type C meeting takes place and its outcome, with written feedback expected within 30 days of the meeting.
Assess whether the recent revenue recovery trend continues, the state of CRO order intake, and whether Neuronata-R sales have resumed.
Confirm whether GMP certification is granted at the Osong ATMP center and the outcome of the equivalency test between the Yongin and Osong production facilities.
Continue monitoring for disclosures related to additional capital raises, convertible or exchangeable bond issuances, and other financing activities.
CorestemChemon's non-clinical CRO segment, which accounts for most of its revenue, has struggled for four consecutive years, weighing on both revenue and operating profit.
However, with the May 2026 domestic label-change approval for Neuronata-R and the August 2026 FDA Type C meeting request, two verifiable milestones—domestic production normalization and global market entry—are now approaching.
Net losses have narrowed for two consecutive quarters, though this remains an improvement from a still-loss-making base.
Capital raises have lowered the debt ratio, but operating cash flow remains negative, and the company itself has noted it could consider divesting business units to raise funds if the CRO market fails to normalize.
Investors may want to track a sequence of verifiable events, including the outcome of the FDA meeting, GMP certification and production restart timing at the Osong plant, and any recovery in CRO order intake. This report does not include a buy or sell recommendation and is provided for informational purposes only.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.